The Use of Tiagabine Augmentation for Treatment-Resistant Anxiety Disorders: A Case Series
Tiagabine is currently approved by the Food and Drug Administration for use in treating certain forms of epilepsy. Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic disorder. This article presents a case series of five patients who were prescribed tiagabine for treatment-resistant anxiety.
Authors
- Thomas L. Schwartz (ORCID: https://orcid.org/0000-0002-0884-8503)
- Maurizio Fava (ORCID: https://orcid.org/0000-0002-4635-0458)
Institutions
- SUNY Upstate Medical University (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4223
- Citations
- 31
- Primary Topic
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00